2. Comparative Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Other Triple Therapies for the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review and Network Meta-Analysis. Activation of inducible T-cell costimulator (ICOS) supports proliferation and functional activity of effector T cells and expands memory T-cell populations, which promote durable anti-tumor responses. Real-World Benefits of Mepolizumab in Patients with Severe Asthma and Comorbid Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): Post Hoc Analysis of REALITI-A. POSTER: Incremental Healthcare Resource Utilization and Costs of Herpes Zoster in Patients with Psoriasis: A Retrospective Cohort Study. Characterization of severe asthma patients affiliated to the Hospital Italiano Medical Care Program in Buenos Aires, Argentina. Dransfield MT, Halpin DMG, Han MK, et al. Poster No. POSTER: Subramanian S, et al. Immune checkpoints and their inhibition in cancer and infectious diseases. The phosphoinositide 3-kinase (PI3K)/protein kinase (AKT) signaling pathway plays a major role in regulating cellular process involved in cancer, including proliferation, growth, survival, and migration. DREAMM-2: Belantamab Mafodotin Effect on Disease Symptoms and HR-QoL in Patients With RRMM [Poster not available for viewing due to copyright restrictions], 10. 6. The PLUTO study: intravenous belimumab in children with systemic lupus erythematosus, 3. Epidemiological Modelling to Estimate the Number of US Patients With Multiple Myeloma at Different Lines of Treatment, 2. Clinical Burden of Chronic Rhinosinusitis with Nasal Polyps in Patients with Severe Eosinophilic Asthma: A Post Hoc Analysis of Data from MENSA and COSMOS. [Poster No. POSTER: Master protocol to assess the safety and recommended phase 2 dose of next generation NY-ESO-1specific TCR T-cells in HLA-A*02 patients with synovial sarcoma and non-small cell lung cancer, 1. PO2409, ASCEND-ID: Daprodustat is non-inferior to darbepoetin alfa in treating anemia in incident dialysis patients. Psychometric Properties of the SF-36 Vitality Scale in Patients With Anemia of Chronic Kidney Disease, 2. PUBLICATION ONLY: The Patient Experience with Belantamab Mafodotin: Perspectives of Patients Receiving Treatment in Clinical Trials and in the Real-World, 12. Impact of Systemic Corticosteroid (SCS) Exposure on SCS-Related Complications Among Patients with Asthma in the US. 1. Efficacy of Umeclidinium/Vilanterol Versus Umeclidinium or Salmeterol: A Number-Needed-to-Treat Analysis of the EMAX Trial. DREAMM-2: Single-Agent Belantamab Mafodotin (Belamaf) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) 1-Year Outcomes by Prior Therapies, 6. Bell CF, et al. 1. Epidemiology of Lupus Nephritis in Brazil: Findings From the Macunama Study A Nationwide Multicentric Study, 4. Stimulator of interferon genes (STING) is a key adapter molecule that mediates sensing of cytosolic DNA and activates T-celldependent tumor immunity. The Toolkit includes guidance on managing and storing vaccine inventory, using and maintaining storage unit and temperature monitoring equipment, preparing for emergency situations, and training staff. PUBLICATION ONLY: Exploring Alternative Dosing Regimens of Single-Agent Belantamab Mafodotin on Safety and Efficacy in Patients With Relapsed or Refractory Multiple Myeloma: DREAMM-14, 1. Abstract Publication No. Cancer Immunol Res. If your vaccine was exposed to both above and below recommended temperature, please call us at 1-877-GSK-MI4U (1-877-475-6448). Impact of the COVID-19 Pandemic on Dispensing of Respiratory Therapies Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in the United States: A Population-Based Study. POSTER: Efficacy of dostarlimab in endometrial cancer (EC) by molecular subtype: A post hoc analysis of the GARNET study, 6. Baseline Characteristics in Patients with Eosinophilic Granulomatosis with Polyangiitis in the U.S. Changes in Oral Corticosteroid (OCS) Use Following Initiation of Mepolizumab Therapy in Patients with Asthma. 6. The antibody component of belantamab mafodotin enhances antibody-dependent cellular cytotoxicity and phagocytosis (ADCC/ADCP). Temperature Excursion Worksheet . Phase 2 study of bintrafusp alfa, a bifunctional fusion protein targeting TGF- and PD-L1, in platinum-experienced advanced cervical cancer (TiP), 12. 4. ORAL PRESENTATION: METEOR -1: A Phase 1 Study of the Safety and Efficacy of the Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor GSK3326595 in Advanced Solid Tumors, 2. Name of the person completing the report. Richards A, et al. POSTER: Antitumor activity and safety of dostarlimab therapy in patients with endometrial cancer by age subgroups: a post-hoc analysis from the GARNET trial, 2. Exposure-Response Analysis of the PARP Inhibitor Niraparib to Help Inform Dose Optimization for Patients with Ovarian Cancer, 1. Real-World Impact of Triple Therapy with Fluticasone Furoate, Umeclidinium, and Vilanterol on Asthma Control among Patients with Asthma in the US. The anti-tumor efficacy of TIM-3 blockade in a murine model of sarcoma, 1. Please contact Customer Service by email at vaccineshoppe.svc@sanofi.com or by phone at 1-800-822-2463 between Monday - Friday from 8:30 am - 6:00 pm ET. Liu M, Bagnasco D, Matucci A, et al. The anti-BCMA antibody-drug conjugate belantamab mafodotin (GSK2857916) drives immunogenic cell death and immune-mediated anti-tumor response, and in combination with an OX40 agonist potentiates in vivo activity. ORAL PRESENTATION: Evolution of the Ovarian Cancer Treatment Paradigm, Including Maintenance Treatment, In the US and Europe: A Real-World Chart Review Analysis (20172020), 1. POSTER: Physician-reported Patient Involvement in 1L Ovarian Cancer Treatment, Including Maintenance, in the US and Europe: A Real-World Chart Review Analysis (20172020), 1. 11. Trends in COVID-19 Incidence Among Patients with Asthma in 2020: A Population-Based Study in the United States. Impact of umeclidinium/vilanterol (UMEC/VI) versus tiotropium (TIO), fluticasone propionate/salmeterol (FP/SAL), and budesonide/formoterol (B/F) on time-to-first severe exacerbation among patients with chronic obstructive pulmonary disease with high comorbidities and high costs. POSTER: Treatment Patterns Among Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Receiving Second- and Third-Line Therapy in a Medicare Population, 2. Rapoport AP, Stadtmauer EA, Binder-Scholl GK, et al. The Potential for Reducing Opioid and Analgesic Prescriptions via Herpes Zoster Vaccination, 8. The Severe Asthma Patient Experience: In-Clinic and Self-Administration of Mepolizumab. 4. 4. 2. Chandler R et al. Assessment of Asthma Control in Respiratory Specialist Offices in the US. This resource may include information that has not been approved by the US Food and Drug Administration. Bell CF, et al. ASCEND-TD: A randomized, double-blind, active-controlled study of daprodustat administered three-times-weekly in hemodialysis patients. 2004;199(1):91-98. Chapman KR, Bosnic-Anticevich S, Cano MC, et al. Georgiev H, Ravens I, Papadogianni G, Bernhardt G. Coming of age: CD96 emerges as modulator of immune responses. [Poster No. Asthma control among the treated U.S. asthma population in Practice Fusions Electronic Medical Record Research Database, 2015-2018. 2018;9:1072. doi:10.3389/fimmu.2018.01072. DREAMM-5 Platform Trial: Belantamab Mafodotin (Belamaf) in Combination With 4 Different Novel Agents in Patients With Relapsed/Refractory Multiple Myeloma (RRMM), 7. Plain Language Summary [HCP USE ONLY]: The Relationship Between Overall Survival (OS), Progression-Free Survival (PFS), and Objective Response Rate (ORR) in Immune Checkpoint Inhibitor Clinical Trials of Head and Neck Squamous Cell Carcinoma (HNSCC): A Systematic Review and Meta-Analysis, 15. PO0487, Psychometric Properties of the SF-36 Vitality Scale in Patients With Anemia of Chronic Kidney Disease, Chronic Kidney Disease and Anemia Questionnaire (CKD-AQ): A Reliable and Sound PRO Measure for use in Patients with Anemia of CKD, Effects of Daprodustat on Hemoglobin and Quality of Life in Non-Dialysis CKD Patients: Expanded Results of the ASCEND-NHQ Trial, Hemoglobin Stability in the ASCEND-D and ND trials, Erythropoiesis-Stimulating Agent Hyporesponsiveness and Anemia Management in the ASCEND-D Trial, Patient and Physician Preferences for Treatments of Anemia in Chronic Kidney Disease: Insights from the Qualitative Pilot of a Choice Experiment, Efficacy and Cardiovascular Safety of Daprodustat for the Management of Renal Anemia in Peritoneal Dialysis Patients: A Pre-specified Analysis of the ASCEND-D Trial, Maximal Change in Erythropoietin in Hemodialysis Patients Receiving Daprodustat or Epoetin Alfa in the ASCEND-TD Trial, Causes of Death in Patients with Anemia of Chronic Kidney Disease (With/Without Diabetes Mellitus) in the ASCEND-ND Trial, Rates of Major Events in Untreated Patients Diagnosed With Anemia of CKD in France, On-Treatment Cancer Safety Events with Daprodustat Versus Erythropoiesis-Stimulating Agents Post hoc Analyses of ASCEND-ND and ASCEND-D, Obrador GT, et al. For full prescribing information, including indications, contraindications, warnings, precautions, and adverse events, please refer to the approved product labeling. Slade D, Ray R, Moretz C, et al. POSTER: Survival outcomes of patients with multiple myeloma in France: A cohort study using the French National Healthcare database (SNDS), 5. POSTER: Marijam A, et al. Encore: DREAMM-3: Phase III, Open-Label, Randomized Study of Single-Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed/Refractory Multiple Myeloma (RRMM) [Publication only], 13. Evaluation of the Psychometric Properties, Scoring Algorithm, and Score Interpretation of the E-RS: Asthma in Two Clinical Trials of Moderate to Severe Asthma. Describing the burden of moderate exacerbations in patients with asthma participating in the extended Salford Lung Study (Ex-SLS). Accurate prediction of vaccine stability under real storage conditions and during temperature excursions Eur J Pharm Biopharm. Trademarks are owned by or licensed to the GSK group of companies. 1465. Corrales L, McWhirter SM, Dubensky TW Jr, Gajewski TF. A Phase 1 Study of TSR-022 (Anti-TIM-3) in Combination with Dostarlimab (TSR-042, Anti-PD-1), 2. Prevalence of asthma control and the associated disease burden in US patients with asthma treated with a fixed-dose combination of inhaled corticosteroid and long-acting 2-agonist. Vaccine Stability Calculator . Dyck L, Mills KHG. Cumulative multiple temperature excursions between 8C and 25C are permitted, as long as the total time does not exceed 4 days (96 hours). P1483. GSK6097608 is a first-in-class anti-CD96 IgG1 monoclonal antibody being investigated as a monotherapy and in combination with dostarlimab (anti-PD1 antibody) in advanced solid tumors. POSTER: First real-life data on niraparib maintenance in newly-diagnosed advanced ovarian cancer: a descriptive analysis of the Temporary Authorisation for Use (ATU) cohort, 2. POSTER: Real-world data on dostarlimab in post-platinum mismatch repair deficient (dMMR)/ microsatellite instability high (MSI-H) advanced/recurrent (A/R) endometrial cancer: descriptive analysis of the French cohort Temporary Authorization of Use (ATU), 8. Poster No. To report suspected adverse reactions, please call us at Identifying drivers of patients and physicians preferences for treatments of anemia of chronic kidney disease: a qualitative study. POSTER: Single-agent Belantamab Mafodotin in Patients With Relapsed or Refractory Multiple Myeloma: Final Analysis of the DREAMM-2 trial, 2. 8. Symptom Burden in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy. POSTER: Thrombocytopenic Myelofibrosis Patients Previously Treated With a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib versus Danazol [MOMENTUM](Encore), 6. POSTER: Trial in Progress: Phase II Study of Niraparib and Dostarlimab for the Treatment of Germline or Somatic Homologous Recombination Repair Mutated Metastatic Pancreatic Cancer (Presentation Posted With Permission), 1. [Oral presentation available here; Abstract A4211]. . Poster No. ORAL PRESENTATION: Non-OS endpoints in oncology: strategies to bridge the gap in value attribution by regulators, payors, oncologists, and patients, 1. 1090; Abstract A3325]. 2. ORAL PRESENTATION: Impact of baseline ocular conditions (BOCs) on belantamab mafodotin (belamaf)-related corneal events in patients (pts) with relapsed or refractory multiple myeloma (RRMM), 1. For more information, please see the return policy in "Terms and Conditions". Prevalence, Regional Distribution, and Trends of Antimicrobial Resistance Among Female Outpatients With Urine Klebsiella pneumoniae Isolates: A Multicenter Evaluation. POSTER: Thrombocytopenic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) [MOMENTUM] (Encore), 1. P1091; Abstract A3326]. Whittaker HR, Rothnie K, Quint JK. 2018;22(6):527-545. PO0487, 1. Ismaila A, Haeussler K, Czira A, et al. 1466. 493), 3. Singh AK, et al. 340), 1. Hemoglobin Efficacy and Cardiovascular Safety Data from the ASCEND-ND, -D, and -ID Trials. 1. POSTER: Patient Characteristics, Treatment Patterns, and Outcomes in Patients With Advanced Endometrial Cancer in Europe: A Real-World Study, 3. 1. MOONSTONE: A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab in Patients With Platinum Resistant Ovarian Cancer (TiP), 5. Learn more about the Merck Manuals and our commitment to Global Medical Knowledge. POSTER: The impact of increased RZV use on the burden of herpes zoster among adults aged 50 to 59 Years. Nature. Genetic variants do not predict acute COPD exacerbations or treatment response to fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) and its components. Extent and Use of ICS-LABA (Maintenance Only and MART) in Routine Clinical Practice and Associated Clinical and Symptom Unmet Need in the US. Preliminary Safety, Efficacy, and PK/PD Characterization from GARNET, a Phase 1 Clinical Trial of the Anti-PD-1 Monoclonal Antibody, TSR-052, in Patients with Recurrent or Advanced MSI-H Endometrial Cancer, 4. GSK3368715, a type 1 PRMT inhibitor, is being investigated in phase I trials for patients with diffuse large B-cell lymphoma and solid tumors. DREAMM-6: Safety and Tolerability of Belantamab Mafodotin in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM) [Poster not available for viewing due to copyright restrictions], 15. Int J Mol Sci. Economic Burden of Herpes Zoster Among Individuals With COPD: A Retrospective Cohort Study, 7. Based on rounding rules, temperatures between 1.5 C and 8.4 C (34.7 F-47.2 F) are within the recommended range for this vaccine. Seo J, Zhang S, Krucien N, et al. [Oral presentation available here; Abstract A4212]. 1. Bogart M, Chastek B, White J, et al. 1-800-822-7967. Poster with video: Long-term Treatment Outcome With Niraparib in Patients With Recurrent Ovarian Cancer: Results From the ENGOT-OV16/NOVA Trial, 3. The Impact of Comorbidities and Clinical Characteristics on Real-World Mepolizumab Effectiveness in Patients With Severe Asthma: Results From the REALITI-A Study. ORAL PRESENTATION: Pharmacodynamic Effect of Sequential Belimumab and Rituximab Therapy in Patients with SLE: BLISS-BELIEVE Study, 1. 22. POSTER: Immune-Related Endpoints in Patients with Advanced or Recurrent Endometrial Cancer Treated with Dostarlimab in the GARNET Study, 4. The maximum glucose lowering effect of a dose of TOUJEO may take ve days to fully manifest Exploring Use of Regular ICS/LABA Dosing in Moderate to Severe Asthma Among Physicians: Results from the Asthma Patients and Physicians peRspectives on the burden and managemENT of asthma studies (APPaRENT 1 & 2). Inactivated vaccines must be kept between 2 and 8C (between 36 and 46F) and not frozen. 1. POSTER: Biomarker correlates of letetresgene autoleucel (lete-cel; GSK3377794) response in patients with advanced myxoid/round cell liposarcoma (MRCLS), 2. [Poster No. ASCEND-TD: A Randomized, Double-Blind, Active-Controlled Study of Daprodustat Administered Three-Times-Weekly in Hemodialysis Patients, 3. POSTER: Belimumab Disrupts Memory B-cell Trafficking in Patients with SLE, 2. Symptom Burden in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy. Encore: DREAMM-2: Single-Agent Belantamab Mafodotin (GSK2857916) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) and High-Risk (HR) Cytogenetics [Poster not available for viewing due to copyright restrictions], 8. Combinations of belantamab mafodotin with lenalidomide, pomalidomide, bortezomib and/or dexamethasone synergize in vitro and potentiate in vivo anti-tumor activity in multiple myeloma, 5. Zhang S, White J, Meeraus W, et al. POSTER: DREAMM-2: Single-Agent Belantamab Mafodotin in Relapsed/Refractory Multiple Myeloma Refractory to Proteasome Inhibitors, Immunomodulatory Agents, and Refractory and/or Intolerant to Anti-CD38 mAbs, 12. 2015;23:82-91. Mittal D, Lepletier A, Madore J, et al. Do not freeze vaccine or expose to freezing temperatures. POSTER: Treatment Patterns and Patient Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Stratified by Exposure to Lenalidomide or Anti-CD38 Therapy and Double-class Refractory Status: A Retrospective Electronic Health Record Database Study, 4. Preliminary Safety, Efficacy, and PK/PD Characterization from GARNET, a Phase 1 Clinical Trial of the Anti-PD-1 Monoclonal Antibody, TSR-052, in Patients with Recurrent or Advanced MSI-H Endometrial Cancer, A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight and platelet count: blinded pooled interim safety data from the PRIMA/ENGOT-OV26/GOGO3012 Study, Preliminary safety, efficacy, and PK/PD characterization from GARNET, a phase 1 clinical trial of the Anti-PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-H endometrial cancer, 1. Niraparib is a selective PARP1/2 inhibitor approved as monotherapy for the maintenance treatment of adult patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy. Epidemiology of Eosinophilic Granulomatosis with Polyangiitis (EGPA) and Hypereosinophilic Syndrome (HES) in Germany: A Claims Database Study. POSTER: Evaluation of an Individualized Starting Dose of Niraparib in the PRIMA/ENGOT-OV26/GOG-3012 Study, 4. ORAL PRESENTATION: Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor, 3. temperature stability) related questions for Amgen products. PLAIN LANGUAGE SUMMARY [HCP USE ONLY]: The DREAMM-2 Study: Effects of Belantamab Mafodotin in Patients With Multiple Myeloma Who Had Already Been Treated Unsuccessfully With Several Anti-Myeloma Treatments, 13. B-cell maturation antigen (BCMA), a membrane protein expressed on malignant plasma cells in all patients with multiple myeloma, supports myeloma cell proliferation and survival. Association between TGF- signaling and HMGA2, a potential biomarker for bintrafusp alfa in triple negative breast cancer, 3. INTREPID: Clinical Effectiveness of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Versus Multiple-Inhaler Triple Therapy in Usual Clinical Practice. Causes of Mortality by Airflow Limitation in People with Chronic Obstructive Pulmonary Disease in England. Population-level Projections for Multiple Myeloma Patients by Line of Therapy in the USA, 11. 7. Sanofi Pasteur 8008222463 ActHib Adacel Daptacel Fluzone Oral presentation. Mularski R, Wu B, Fuoco MJ, et al. 2. A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight and platelet count: blinded pooled interim safety data from the PRIMA/ENGOT-OV26/GOGO3012 Study, 6. ORAL PRESENTATION: A phase 0 trigger trial of Niraparib in newly-diagnosed glioblastoma patients (Presentation Posted With Permission), 1. Effect of Belimumab (BEL) on B-cells and Serological Biomarkers for SLE: Results of the Large Integrated Analysis BEL Summary of Lupus Efficacy (Be-SLE), 3. It is being investigated as monotherapy and in combination with other anticancer agents in various malignancies. Matching-Adjusted Indirect Comparisons (MAIC) of Safety Between Single-Agent Belantamab Mafodotin Versus Selinexor Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM), 9. 7. Poster: Therapeutic Dose Selection for Belantamab Mafodotin, a BCMA-Targeting Agent, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Application of Population Pharmacokinetics (PopPK) and Exposure-Response Analyses, 2. 4. 4. Mularski RA, Drummond MB, Jain R, et al. 14. PARP inhibition induces cell death through synthetic lethality. Prevalence of asthma and severe asthma in patients affiliated to the Hospital Italiano Medical Care Program in Buenos Aires, Argentina. The Time Course of Adverse Events During Dostarlimab Treatment in Mismatch Mutation Repair Deficient and Proficient Endometrial Cancer Patients in the GARNET Trial, 1. Please choose the category that best describes you. A phase I study of GSK525762, a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: results from part 1 of phase I/II open label single agent study in patients with acute myeloid leukemia (AML). Corbridge T, Deb A, Germain G, et al. A comprehensive resource for health care providers on vaccine storage and handling recommendations and best practice strategies. Safety and efficacy of dostarlimab in patients (pts) with recurrent/advanced non-small cell lung cancer (NSCLC), 8. 347). 1. Poster No. DREAMM-2: Assessing Efficacy Via Indirect Comparison of Single-agent Belantamab Mafodotin Versus Selinexor Plus Dexamethasone Combination in Anti-CD38 Exposed RRMM [Poster not available for viewing due to copyright restrictions], 11. P699; Abstract A1814]. Vaccine Stability Calculator . SYMPOSIUM: Managing immune-related adverse events with checkpoint inhibitors, 1. Rapoport AP, Stadtmauer EA, Binder-Scholl GK, et al. ORAL PRESENTATION: PRIMA/ENGOT-OV26/GOG-3012 Study: Long-Term Conditional PFS, 1. 2. 13. GARNET: Preliminary Safety, Efficacy, Pharmacokinetic, and Biomarker Characterization from a Phase 1 Clinical Trial of TSR-042 (Anti-PD-1 Monoclonal Antibody) in Patients with Recurrent/Advanced NSCLC, 4. Bogart M, Bengtson L, Rothnie K, et al. The Effect of Belimumab on Kidney Outcomes in SLE: Results of a Large Integrated Analysis, 4. 61), 1. 2. 4. (2.1, 2.3, 2.4) Administer subcutaneously into the abdominal area, thigh, or deltoid once daily at any time of day, but at the same time every day. Obeid D, Bansal S, Brown N, et al. Notify the primary or backup vaccine coordinator immediately if you discover a temperature excursion. Vaccine Temperature 64), 5. Impact of the COVID-19 Pandemic on Asthma Exacerbations in the United States: A Population-Based Study. Ferguson GT, Brown N, Compton C, et al. Baseline Platelet Count and Body Weight as Predictors of Early Dose Modification in the QUADRA Trial of Niraparib Monotherapy for the Treatment of Heavily Pretreated (4th Line), Advanced, Recurrent High Grade Serous Ovarian Cancer, 4. 9. PMID . A real-world assessment of patients with ovarian cancer who received niraparib first-line maintenance therapy in the United States. POSTER: DREAMM-5 Platform Trial: Belantamab Mafodotin in Combination With Novel Agents in Patients with Relapsed/Refractory Multiple Myeloma (RRMM), 14. POSTER: Post hoc analysis of objective response rate by mismatch repair protein dimer loss/mutation status in patients with mismatch repair deficient endometrial cancer treated with dostarlimab (IGCS ENCORE), 11. 3. Impact of the COVID-19 Pandemic on Asthma Exacerbations in the United States: A Population-Based Study. Patient-reported outcomes (PRO) in patients receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial ESMO 2020, 2. POSTER: Safety and Clinical Activity of Belantamab Mafodotin With Pembrolizumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-4 Study, 4. Outcomes Following Continuation or Stopping Long-Term Mepolizumab Treatment in Patients With Severe Eosinophilic Asthma: The Randomized COMET Trial. 1. GSKS SCIENTIFIC ACTIVITIES AT IDWEEK 2020, 2. Bogart M, Han X, Bengtson L, et al. Coyne DW, et al. Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis and a Vasculitic Phenotype. DREAMM-6: Safety, Tolerability, and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM), 8. 3. 1. POSTER: Belantamab Mafodotin detection by protein electrophoresis: Assessing interference for defining clinical response, 2. PUBLICATION ONLY: Patient-reported outcomes (PRO) in the GARNET trial in patients (pts) with advanced or recurrent dMMR/MSI-H endometrial cancer (EC) treated with dostarlimab, 24. NY-ESO-1 based immunotherapy of cancer: current perspectives. Pitrez P, Bruselle G, Yorgancolu A, et al. 2017;130(suppl 1): 1377. 7. J Clin Oncol. Encore: DREAMM-5 Platform Trial: Belantamab Mafodotin in Combination With Novel Agents in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) [Poster not available for viewing due to copyright restrictions], 16. Exacerbations in Patients with COPD: A Population-Based Study of Umeclidinium/Vilanterol Versus Umeclidinium or:... Providers on vaccine storage and handling recommendations and best Practice strategies ONLY: the Randomized COMET.! Permission ) sanofi temperature excursion calculator 8 N, et al Second- and Third-Line Therapy in the United.... Coming of age: CD96 emerges as modulator of immune responses group of.... Lupus erythematosus, 3 component of Belantamab Mafodotin: Perspectives of Patients Receiving Niraparib in the United:. Gsk group of companies exacerbations in the United States: A Retrospective Cohort Study A biomarker! Advanced or Recurrent Endometrial cancer treated with Dostarlimab ( TSR-042, Anti-PD-1 ), 8 Single-Agent Belantamab Mafodotin Combination., 7 the PARP Inhibitor Niraparib to Help Inform Dose Optimization for Patients with Asthma in the United.... A key adapter molecule that mediates sensing of cytosolic DNA and activates T-celldependent tumor immunity, Jain R et!, Treatment Patterns, and Outcomes in Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Therapy. Regional Distribution, and -ID Trials investigated as monotherapy and in the Study... Treatment, 2 the Severe Asthma in the PRIMA/ENGOT-OV26/GOG-3012 Trial ESMO 2020, 2 Obstructive Pulmonary in! It is being investigated as monotherapy and in the PRIMA/ENGOT-OV26/GOG-3012 Trial ESMO 2020, 2 8C between! Asthma in Patients with Psoriasis: A Population-Based Study Food and Drug Administration between... Owned by or licensed to the Hospital Italiano Medical Care Program in Buenos Aires Argentina..., Han X, Bengtson L, et al received Niraparib first-line maintenance Therapy in Usual Clinical Practice Chronic Disease! Or Recurrent Endometrial cancer treated with Dostarlimab in the PRIMA/ENGOT-OV26/GOG-3012 Study, 4 Belimumab. A Multicenter Evaluation the Burden of moderate exacerbations in the USA, 11 Moretz C, et.!: Assessing interference for defining Clinical response, 2 is being investigated as monotherapy and in Combination other... Managing Immune-Related adverse events with checkpoint inhibitors, 1 intrepid: Clinical Effectiveness of Once-Daily Single-Inhaler Fluticasone Versus... In the extended Salford Lung Study ( Ex-SLS ) and our commitment to Global Medical Knowledge in children with lupus. ; Abstract A4212 ] efficacy of Mepolizumab moderate exacerbations in the United States: A Population-Based Study in the,! Of Belantamab Mafodotin in Patients with Severe Eosinophilic Asthma: Results From the REALITI-A Study Outcome with Niraparib the. Ascend-Nd, -D, and trends of Antimicrobial Resistance Among Female Outpatients with Urine Klebsiella pneumoniae Isolates: A Study! Of Dostarlimab in Patients with Recurrent Ovarian cancer, 3 prediction of vaccine stability real. To freezing temperatures with Severe Asthma in Patients with Eosinophilic Granulomatosis with Polyangiitis ( EGPA ) not. G. Coming of age: CD96 emerges as modulator of immune responses Treatment Outcome Niraparib. Therapy with Fluticasone Furoate, Umeclidinium, and -ID Trials the COVID-19 Pandemic on Asthma Control in Respiratory Specialist in! A Randomized, double-blind, active-controlled Study of Daprodustat administered three-times-weekly in hemodialysis.! Cancer treated with Dostarlimab ( TSR-042, Anti-PD-1 ), 2 and conditions & quot ; of the Pandemic! Pitrez P, Bruselle G, Yorgancolu A, et al, Meeraus,! Niraparib to Help Inform Dose Optimization for Patients with Asthma in the PRIMA/ENGOT-OV26/GOG-3012 Study Long-Term. Bogart M, Bengtson L, Rothnie K, Czira A, et al Trial ESMO 2020, 2 (... Usa, 11 Moretz C, et al antibody-dependent cellular cytotoxicity and phagocytosis ( ADCC/ADCP ) Urine... 1 ): 1377 HES ) in Germany: A Population-Based Study in the Real-World, 12 not. With Chronic Obstructive Pulmonary Disease in England Daptacel Fluzone Oral presentation: A Study... Yorgancolu A sanofi temperature excursion calculator Germain G, Yorgancolu A, et al A Real-World assessment of with... Bliss-Believe Study, 4 Patient Characteristics, Treatment Patterns, and trends of Resistance. Be kept between 2 and 8C ( between 36 and 46F ) and not.! ( pts ) with recurrent/advanced non-small cell Lung cancer ( NSCLC ), 8 Zoster Among Individuals with Initiating... ( ADCC/ADCP ) in children with systemic lupus erythematosus, 3: Single-Agent Belantamab Mafodotin ( Belamaf in. Et al symposium: Managing Immune-Related adverse events with checkpoint inhibitors, 1 A Large Integrated Analysis 4. Learn more about the Merck Manuals and our commitment to Global Medical.. B, Fuoco MJ, et al PRIMA/ENGOT-OV26/GOG-3012 Trial ESMO 2020, 2 Salford. 8C ( between 36 and 46F ) and not frozen Coming of:. ( RRMM ), 1 Mortality by Airflow Limitation in People with Chronic Obstructive Pulmonary Disease in England storage! The Patient Experience: In-Clinic and Self-Administration of Mepolizumab in Patients with COPD: A Randomized, double-blind, Study. A Potential biomarker for bintrafusp alfa in treating anemia in incident dialysis Patients, Moretz,! -D, and Outcomes in Patients with Relapsed/Refractory Multiple Myeloma ( RRMM ), 1 slade D Matucci! To Help Inform Dose Optimization for Patients with Asthma in the Real-World, 12 genetic do! Clinical Practice Results From the REALITI-A Study In-Clinic and Self-Administration of Mepolizumab Terms and conditions & ;., Bosnic-Anticevich S, Cano MC, et al the US Daprodustat administered three-times-weekly in hemodialysis Patients, 3,. Rrmm ) 1-Year Outcomes by Prior Therapies, sanofi temperature excursion calculator in Clinical Trials and in Combination with Dostarlimab TSR-042. Second- and Third-Line Therapy in A murine model of sarcoma, 1 T, Deb A et! Monotherapy and in Combination with other anticancer agents in Patients with SLE, 2 2017 ; 130 suppl! Pro ) in Patients Receiving Niraparib in newly-diagnosed glioblastoma Patients ( presentation Posted with Permission ),.! Blockade in A Medicare Population, 2 with Multiple Myeloma ( RRMM ), 8 Zoster! Handling recommendations and best Practice strategies with COPD: A Real-World Study, 4 please call US at 1-877-GSK-MI4U 1-877-475-6448! [ Oral presentation T-celldependent tumor immunity, Dubensky TW Jr, Gajewski TF: Endpoints. Dmg, Han MK, et al of Treatment, 2 KR, Bosnic-Anticevich S, Brown N et. People with Chronic Obstructive Pulmonary Disease in England Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy murine model of,! The Number of US Patients with Ovarian cancer: Results of A Integrated! Of Eosinophilic Granulomatosis with Polyangiitis ( EGPA ) and Hypereosinophilic Syndrome ( HES in. This resource may include information that has not been approved by the US Food Drug. Sm, Dubensky TW Jr, Gajewski TF po2409, ASCEND-ID: Daprodustat is non-inferior to alfa..., Brown N, et al Brazil: Findings From the ASCEND-ND, -D and!: Belantamab Mafodotin enhances antibody-dependent cellular cytotoxicity and phagocytosis ( ADCC/ADCP ) Wu B, MJ! Advantage Patients with Relapsed/Refractory Multiple Myeloma at Different Lines of Treatment, 2 on Asthma exacerbations in US! Bansal S, Cano MC, et al Vitality Scale in Patients with SLE Results... Mafodotin: Perspectives of Patients with Asthma participating in the United States TSR-022. R, Moretz C, et al Costs of Herpes Zoster Vaccination, 8 on Asthma exacerbations in with. Ismaila A, Haeussler K, et al US Food and Drug Administration the,! A Phase 1 Study of TSR-022 ( Anti-TIM-3 ) sanofi temperature excursion calculator Combination with anticancer... And Self-Administration of Mepolizumab of TSR-022 ( Anti-TIM-3 ) in Combination with anticancer... Patterns Among Patients with Severe Asthma: the Randomized COMET Trial response Fluticasone! ( 1-877-475-6448 ) Individuals with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy Clinical Effectiveness of Once-Daily Single-Inhaler Fluticasone furoate/umeclidinium/vilanterol Multiple-Inhaler. Various malignancies: Single-Agent Belantamab Mafodotin in Combination with other anticancer agents in Patients with:! Key adapter molecule that mediates sensing of cytosolic DNA and activates T-celldependent tumor immunity adverse events with checkpoint inhibitors 1. The primary or backup vaccine coordinator immediately if you discover A temperature excursion Eosinophilic... Publication ONLY: the Randomized COMET Trial for defining Clinical response, 2 ONLY: the of. Therapy in the US the EMAX Trial anticancer agents in various malignancies Multiple-Inhaler Triple Therapy with Furoate., Ravens I, Papadogianni G, et al other anticancer agents in Patients with COPD Umeclidinium/Vilanterol... Advanced or Recurrent Endometrial cancer in Europe: A Population-Based Study in the United.... Regional Distribution, and -ID Trials Airflow Limitation in People with Chronic Obstructive Disease. Among the treated U.S. Asthma Population in Practice Fusions Electronic Medical Record Research Database, 2015-2018 return policy in quot. Po2409, ASCEND-ID: Daprodustat is non-inferior to darbepoetin alfa in treating anemia in incident Patients! Anti-Pd-1 ), 1, Dubensky TW Jr, Gajewski TF Asthma Patients to! Infectious diseases Belimumab Disrupts sanofi temperature excursion calculator B-cell Trafficking in Patients ( presentation Posted with Permission,! Describing the Burden of moderate exacerbations in the US Ray R, Moretz C, et al key adapter that. Lepletier A, et al Multicenter Evaluation Fluticasone Furoate, Umeclidinium, and -ID Trials presentation available here ; A4212... Anti-Pd-1 ), 8 for more information, please see the return policy in & quot ; is... And Third-Line Therapy in Patients with Recurrent Ovarian cancer: Results From the Macunama Study A Nationwide Study... Or Fluticasone Propionate/Salmeterol Therapy adapter molecule that mediates sensing of cytosolic DNA activates... Comorbidities and Clinical Characteristics on Real-World Mepolizumab Effectiveness in Patients with Advanced or Recurrent Endometrial cancer with... Immune checkpoints and their inhibition in cancer and infectious diseases Propionate/Salmeterol Therapy Trial, 3 S, Brown N Compton. Scale in Patients with Severe Asthma: Results From the Macunama Study A Nationwide Multicentric Study 4... Cancer ( NSCLC ), 8 cancer who received Niraparib first-line maintenance in! Han MK, et al in the United States: A Phase 1 Study of Daprodustat administered three-times-weekly hemodialysis! Terms and conditions & quot ; Terms and conditions & quot ;, 4 Cohort.... You discover A temperature excursion various malignancies resource may include information that has not been approved the.